Ionis Pharmaceuticals Inc IONS

NAS: IONS | ISIN: US4622221004 17/01/2025

31,43 USD (-2,63%)

(-2,63%) 17/01/2025

Grafiek Ionis Pharmaceuticals Inc

Grafiek Ionis Pharmaceuticals Inc

1 dag1d -2,63%
1 week1w -10,05%
1 maand1m -11,79%
3 maanden3m -19,41%
6 maanden6m -37,90%
1 jaar1j -38,38%
5 jaar5j -47,63%

Ionis Pharmaceuticals Inc in het nieuws

Toon enkel gratis nieuws

10 september 2024 · Ionis announces pricing of $500.3 million public offering · Persbericht

9 september 2024 · Ionis announces proposed public offering of common stock · Persbericht

28 augustus 2024 · Ionis to present at upcoming investor conferences · Persbericht

1 augustus 2024 · Ionis reports second quarter 2024 financial results · Persbericht

31 juli 2024 · Alcyone Therapeutics Announces Continued Enrollment Approval from FDA of the PIERRE Pivotal IDE Clinical Study of the ThecaFlex DRx™ System for Administration of nusinersen · Persbericht

22 juli 2024 · Ionis announces positive detailed results from the HALOS Study of ION582 in people with Angelman syndrome · Persbericht

19 juli 2024 · Ionis to hold second quarter 2024 financial results webcast · Persbericht

18 juli 2024 · Ionis completes enrollment in pivotal trial evaluating zilganersen in people living with Alexander disease · Persbericht

8 juli 2024 · Ionis announces webcast to report HALOS study results for ION582 in Angelman syndrome · Persbericht

25 juni 2024 · Ionis announces olezarsen FCS New Drug Application accepted for Priority Review and enrollment in Phase 3 sHTG program completed · Persbericht

Profiel Ionis Pharmaceuticals Inc

Fabricage van farmaceutische preparaten

Gezondheidstechnologie

Website: www.ionispharma.com

Hoofdzetel: Carlsbad, California Verenigde Staten

CEO: Brett Monia

Werknemers: 920

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe